Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium ...
Nov 19, 2026
0
6









